644 related articles for article (PubMed ID: 17312309)
41. Managing bone health with zoledronic acid: a review of randomized clinical study results.
Hadji P
Climacteric; 2011 Jun; 14(3):321-32. PubMed ID: 21182431
[TBL] [Abstract][Full Text] [Related]
42. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
[TBL] [Abstract][Full Text] [Related]
43. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
[TBL] [Abstract][Full Text] [Related]
44. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
Suominen MI; Rissanen JP; Käkönen R; Fagerlund KM; Alhoniemi E; Mumberg D; Ziegelbauer K; Halleen JM; Käkönen SM; Scholz A
J Natl Cancer Inst; 2013 Jun; 105(12):908-16. PubMed ID: 23682134
[TBL] [Abstract][Full Text] [Related]
45. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
46. Comparison of effects of clodronate and zoledronic acid on the repair of maxilla surgical wounds - histomorphometric, receptor activator of nuclear factor-kB ligand, osteoprotegerin, von Willebrand factor, and caspase-3 evaluation.
Vasconcelos AC; Berti-Couto SA; Azambuja AA; Salum FG; Figueiredo MA; da Silva VD; Cherubini K
J Oral Pathol Med; 2012 Oct; 41(9):702-12. PubMed ID: 22417074
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
Paterson A; McCloskey E; Redzepovic J; Ott I; Gust R
J Int Med Res; 2008; 36(3):400-13. PubMed ID: 18534121
[TBL] [Abstract][Full Text] [Related]
48. [Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Diel IJ
Gynakol Geburtshilfliche Rundsch; 1998; 38(2):64-71. PubMed ID: 9815520
[TBL] [Abstract][Full Text] [Related]
49. Effect of intermittent and daily regimens of minodronic Acid on bone metabolism in an ovariectomized rat model of osteoporosis.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Yamada H; Kawada N; Kawabata K
Calcif Tissue Int; 2014 Aug; 95(2):166-73. PubMed ID: 24903232
[TBL] [Abstract][Full Text] [Related]
50. Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.
Previdi S; Scolari F; Chilà R; Ricci F; Abbadessa G; Broggini M
PLoS One; 2013; 8(11):e79101. PubMed ID: 24260160
[TBL] [Abstract][Full Text] [Related]
51. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
52. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.
Gnant M
Curr Cancer Drug Targets; 2009 Nov; 9(7):824-33. PubMed ID: 20025570
[TBL] [Abstract][Full Text] [Related]
53. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
[TBL] [Abstract][Full Text] [Related]
54. Clodronate in the prevention and treatment of skeletal metastasis.
Gulley J; Dahut WL
Expert Rev Anticancer Ther; 2005 Apr; 5(2):221-30. PubMed ID: 15877520
[TBL] [Abstract][Full Text] [Related]
55. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
[TBL] [Abstract][Full Text] [Related]
56. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
Caffo O
Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
[No Abstract] [Full Text] [Related]
57. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
58. Bisphosphonates as anticancer therapy for early breast cancer.
Mahtani R; Jahanzeb M
Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
[TBL] [Abstract][Full Text] [Related]
59. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.
Amanat N; McDonald M; Godfrey C; Bilston L; Little D
J Bone Miner Res; 2007 Jun; 22(6):867-76. PubMed ID: 17371160
[TBL] [Abstract][Full Text] [Related]
60. Are new-generation bisphosphonates effective for the inhibition of calcium oxalate stone formation in a rat model?
Basok EK; Basaran A; Atsu N; Yildirim A; Tokuc R
Urol Int; 2008; 81(3):325-9. PubMed ID: 18931552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
